Welcome to the LINXS workshop on Biomedical Imaging for drug discovery/development - Opportunities for MAXIV
Abstract
This workshop is an educational event on drug discovery/development and biomedical imaging. The specific focus is to demonstrate the opportunities for biomedical applications using synchrotron imaging in the drug development pipeline. Imaging of tissue ex-vivo as well as in-vivo imaging will be within the scope. The process to develop new pharmaceuticals will be reviewed and how, at present, biomedical imaging is used in this process. From current biomedical applications using synchrotron imaging, opportunities for applications to drug development will be outlined and discussed.
This workshop will be of interest to scientists engaged in biomedical research, bioimaging or drug development in both academia and industry.
When: Oct 19, 08:30 - 13.30
Where: at LINXS (Scheelvägen 19), with the digital possibility (Zoom)
Registration deadline: October 13. After that date we will accept only digital participations.
Please inform us in case of cancelation for physical participation (avoid food waste and costs). There will be a fee of 200 SEK for no-shows.
Programme Agenda
08:30 - 08:45 Introduction Lars E. Olsson and Oxsana Klementieva (moderator) Lund University
08:45 - 09:15 Drug discovery and development from target indentification to 'New Drug Application' Karin von Wachenfeldt, Truly Translational, Lund
09:15 - 09:45 Decision making in drug discovery/development using in-vivo animal imaging Leif Hultin, AstraZeneca, Mölndal
09:45 - 10:15 Coffee break
10:15 - 10:40 Limitations of conventional imaging methods X-ray, SPECT, PET, MRI, US Lars E. Olsson, Lund University
10:40 - 11:05 Opportunities with synchrotron imaging for drug discovery/development Martin Bech, Lund University
11:05 - 11:35 Synchrotron-based pulmonary imaging: current and future challenges in interdisciplinary data analysis, Goran Lovric, Paul Scherrer Institute
11:35 - 12:30 Biomedical imaging for drug discovery/development Opportunities for MAX IV. Discussion, summing up. Moderator Marjolein Thunnissen, Division director MAX IV Laboratory. Panel: Speakers above and Jens Lagerstedt, Novo Nordisk
12:30-13:30 Lunch
Organisers: For questions please contact Lars E Olsson <lars_e.olsson@med.lu.se>, or Nina Ahlbeck <nina.ahlbeck@fsi.lu.se> on practical matters.